Treatment algorithms in systemic lupus erythematosus

Arthritis Care and Research

Volumn 67, Issue 9, 2015, Pages 1237-1245

  Muangchan, Chayawee ^a,b   Van Vollenhoven, Ronald F ^c   Bernatsky, Sasha R ^d   Smith, C Douglas ^e   Hudson, Marie ^f   Inanç, Murat ^g   Rothfield, Naomi F ^h   Nash, Peter T ⁱ   Furie, Richard A ^j   Senécal, Jean Luc ^k   Chandran, Vinod ^l   Burgos Vargas, Ruben ^m   Ramsey Goldman, Rosalind ⁿ   Pope, Janet E ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g ISTANBUL UNIVERSITY   (Turkey)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j Northwell Health   (United States)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; PROSTANOID; RITUXIMAB; STEROID; SUNSCREEN; THROMBIN INHIBITOR; WARFARIN;

ALGORITHM; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTHRITIS; ARTICLE; CUTANEOUS VASCULITIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG ALVEOLITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONONEUROPATHY MULTIPLEX; PERICARDITIS; PLASMAPHERESIS; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT INDICATION; VASCULITIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; AGED; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PRACTICE GUIDELINE; QUESTIONNAIRE;

AGED; ALGORITHMS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SURVEYS AND QUESTIONNAIRES;

EID: 84940102785     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22589     Document Type: Article

References (58)

1. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR., New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012; 8: 522-33.
2. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al., EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008; 67: 195-205.
3. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al., EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-82.
4. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al., Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
5. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
6. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
7. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al., Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab Study. Arthritis Rheum 2012; 64: 1215-26.
8. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4.
9. Rahman P, Aguero S, Gladman DD, Hallett D, Urowitz MB., Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000; 9: 672-5.
10. Bruce IN, Urowitz MB, Gladman DD, Hallett DC., Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137-43.
11. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley M., Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62: 211-21.
12. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda- Limon JM, et al., Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-5.
13. Martinez-Taboada VM, Alonso RB, Armona J, Fernandez-Sueiro JL, Gonzalez Vela C, Rodriguez-Valverde V., Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Lupus 1996; 5: 74-6.
14. Narvaez J, Rios-Rodriguez V, de la Fuente D, Estrada P, Lopez-Vives L, Gomez-Vaquero C, et al., Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 2011; 41: 364-72.
15. Milstone AM, Meyers K, Elia J., Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 2005; 24: 394-7.
16. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al., Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-31.
17. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N., Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282-7.
18. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M., Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-9.
19. Chan YK, Li EK, Tam LS, Chow LT, Ng HK., Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scand J Rheumatol 2003; 32: 306-8.
20. Law WG, Thong BY, Lian TY, Kong KO, Chng HH., Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus 2005; 14: 827-31.
21. Chung JW, Joe DY, Park HJ, Kim HA, Park HS, Suh CH., Clinical characteristics of lupus myocarditis in Korea. Rheumatol Int 2008; 28: 275-80.
22. Van der Laan-Baalbergen NE, Mollema SA, Kritikos H, Schoe A, Huizinga TW, Bax JJ, et al., Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus. Neth J Med 2009; 67: 295-301.
23. Appenzeller S, Pineau CA, Clarke AE., Acute lupus myocarditis: clinical features and outcome. Lupus 2011; 20: 981-8.
24. Rosenbaum E, Krebs E, Cohen M, Tiliakos A, Derk CT., The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. Lupus 2009; 18: 608-12.
25. Kamata Y, Iwamoto M, Aoki Y, Kishaba Y, Nagashima T, Nara H, et al., Massive intractable pericardial effusion in a patient with systemic lupus erythematosus treated successfully with pericardial fenestration alone. Lupus 2008; 17: 1033-5.
26. Weich HS, Burgess LJ, Reuter H, Brice EA, Doubell AF., Large pericardial effusions due to systemic lupus erythematosus: a report of eight cases. Lupus 2005; 14: 450-7.
27. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al, and the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
28. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al., A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
29. Boumpas DT, Barez S, Klippel JH, Balow JE., Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112: 674-7.
30. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al., Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002; 29: 75-83.
31. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al., Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78: 275-80.
32. Aledort LM, Salama A, Kovaleva L, Robak T, Newland AC, Nugent DJ, et al., Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura. Hematology 2007; 12: 289-95.
33. Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A., Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis 2013; 24: 284-96.
34. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al., Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121: 537-45.
35. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL., Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol 2013; 160: 538-46.
36. Tsokos GC, Caughman SW, Klippel JH., Successful treatment of generalized discoid skin lesions with azathioprine: its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985; 121: 1323-5.
37. Shehade S., Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1986; 122: 376-7.
38. Werth V, Franks A Jr., Treatment of discoid skin lesions with azathioprine. Arch Dermatol 1986; 122: 746-7.
39. Ashinoff R, Werth VP, Franks AG Jr., Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988; 19: 961-5.
40. Callen JP, Spencer LV, Burruss JB, Holtman J., Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-22.
41. Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT., Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus. Lupus 2010; 19: 744-7.
42. Lampropoulos CE, Sangle S, Harrison P, Hughes GR, D'Cruz DP., Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43: 1383-5.
43. Sugano M, Shintani Y, Kobayashi K, Sakakibara N, Isomura I, Morita A., Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006; 33: 887-91.
44. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al., Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65: 54-64.
45. Carneiro JR, Sato EI., Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26: 1275-9.
46. Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ., Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis 2012; 15: 62-8.
47. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-18.
48. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al., Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
49. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al., A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
50. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al., Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71: 1833-8.
51. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, et al., Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61: 74-87.
52. Feng L, Deng J, Huo DM, Wu QY, Liao YH., Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton) 2013; 18: 104-10.
53. Weidenbusch M, Rommele C, Schrottle A, Anders HJ., Beyond the LUNAR trial: efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-11.
54. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, et al., Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-64.
55. Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, et al., Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010; 19: 1281-9.
56. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al., Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011; 57: 235-44.
57. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al., Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012; 27: 1467-72.
58. Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al., Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012; 17: 352-7.